Shopping Cart
Remove All
Your shopping cart is currently empty
Miptenalimab
(Synonyms: BI-754111) Copy Product Info
🥰Excellent
Synonyms: BI-754111
Catalog No. T81790 Copy Product Info
🥰Excellent
Miptenalimab is a humanized monoclonal antibody targeting human lymphocyte-activation gene 3 (LAG-3/CD223). By specifically binding to LAG-3, the antibody blocks its interaction with ligands such as Major Histocompatibility Complex II (MHC II), thereby relieving the inhibitory signals on effector T cells and NK cells. As an immune checkpoint inhibitor, Miptenalimab is designed to reactivate exhausted T cells and enhance anti-tumor immune responses.
Miptenalimab
Cas No. 2249882-55-9
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $392 | 4-6 weeks | 4-6 weeks | |
| 5 mg | $1,200 | 4-6 weeks | 4-6 weeks | |
| 10 mg | $1,920 | 4-6 weeks | 4-6 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Miptenalimab is a humanized monoclonal antibody targeting human lymphocyte-activation gene 3 (LAG-3/CD223). By specifically binding to LAG-3, the antibody blocks its interaction with ligands such as Major Histocompatibility Complex II (MHC II), thereby relieving the inhibitory signals on effector T cells and NK cells. As an immune checkpoint inhibitor, Miptenalimab is designed to reactivate exhausted T cells and enhance anti-tumor immune responses. |
| In vitro | In functional T-cell assays, Miptenalimab (BI 754111) effectively blocked the interaction between LAG-3 and MHC II. When combined with the anti-PD-1 antibody Ezabenlimab, it significantly increased the production of IFN-gamma and IL-2 in antigen-specific T-cell stimulation models, demonstrating a synergistic boost to immune cell activation [1]. |
| In vivo | In humanized mouse models bearing tumor xenografts, the combined blockade of LAG-3 by Miptenalimab and PD-1 led to increased infiltration of effector T cells into the tumor microenvironment and resulted in superior tumor growth inhibition compared to monotherapy [1]. |
| Synonyms | BI-754111 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | LAG-3 |
| Cas No. | 2249882-55-9 |
| Isotype | IgG4 (S228P) |
| Recommended Isotype Control |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Miptenalimab in vivo | Miptenalimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.